Epigene Labs

📣 We are proud to announce our multi-year expansion of collaboration with Servier to advance AI-driven precision oncology R&D! This collaboration combines our mCUBE platform, which leverages AI to seamlessly integrate multi-omic data from various sources, with Servier's expertise in precision oncology. The goal is to accelerate and increase the precision of Servier's oncology clinical trials by improving patient selection, advancing disease modeling, and identifying biomarkers with greater accuracy. Read more on: https://lnkd.in/dE-SB2hy Discover our mission on our website: https://lnkd.in/dardshpv A big thank you to Fabien Schmidlin, Celine Lefebvre, Chloé Leprêtre, and the many teams at Servier – across data, biology, business, and beyond – for their invaluable contributions in making this new and ambitious phase of our collaboration a reality.

At Epigene Labs, we stand up for science. It's a no brainer.

Breaking the Myths: Let’s talk about Cancer Research! 🎗️ “Cancer is a death sentence.” “There hasn’t been any real progress.” “Research takes too long to make a difference.” These misconceptions are still far too common. But science proves otherwise—day after day. 🙌 Thanks to research innovation, we are witnessing groundbreaking discoveries that improve survival rates, enhance treatments, and bring us closer to a future where cancer is no longer a threat. Let’s debunk these myths together—let us know which scientific breakthrough or research has inspired you. We believe in the power of science to save lives—and that together, we can amplify its impact. Let’s keep hope alive together.

Meet our Co-founder & CEO at LSX - partnering for Life Science eXecutives's Investival Showcase on March 10-11!

100,000 Patient Samples And Counting. The Real Question: How Will You Use Them? 🔬 What started as a vision is now a reality—we have officially reached 100,000 patient samples integrated into mCUBE, spanning 30+ cancer types, including single-cell and transcriptomic data. This milestone will power the future of precision medicine, starting with oncology research. What does this mean? 🎯 100,000 patient samples harmonized, structured, and ready to drive innovation 🎯 Identification of novel therapeutic targets 🎯 Refinement of biomarker hypotheses and disease indications to support early R&D programs 🎯 Enabling drug repurposing by uncovering new indications for existing drugs A massive shoutout to everyone involved, particularly our Product Development & Data Integration Squad! 👏 Your interdisciplinary expertise and dedication made this possible, and this is just the beginning. What’s next? We’ve identified 1M+ of such relevant patient samples, so we’re working hard to make each count in accelerating precision oncology R&D in biopharma.

What is the status of biotech innovation in Europe in 2025? 🇪🇺 This map gives a clear, data-driven overview of the key companies shaping the European biotech scene. A big thank you to Philip Hemme for compiling and sharing this valuable resource! Want access to the full database behind the map? Just follow the instructions in his post below. 👇

Cancer makes the cover of TIME magazine with alarming news: it's now stickying us as young adults. 📈 More and more people under 50 are being diagnosed with cancer, with alarming increases in colorectal, breast, and gastrointestinal cancers. Yet, many cases are detected too late due to the misconception that cancer is an "older person’s disease." 🚨 The rise in cancer cases among young adults isn’t just about lifestyle. Dr. Cathy Eng (Vanderbilt University's Ingram Cancer Center) notes that many of her patients are incredibly healthy—nonsmokers, vegetarians, even athletes—yet still develop aggressive cancers. Dr. Andrea Cercek (Memorial Sloan Kettering Cancer Center) highlights an unsettling trend: some patients in their 20s and teens develop tumors that biologically resemble those found in 80-year-olds. The usual risk factors don’t fully explain this surge, raising urgent questions about hidden environmental or genetic influences. Early detection & research are more critical than ever. We need to rethink how we identify, prevent, and treat cancer in younger generations. Find this insightful TIME article in the comments 👇

Big news! We’re in Le Point “Palmarès des Inventeurs 2025” (2025 Inventors’ Ranking)! A recognition of the work we do to push the boundaries of artificial intelligence and next-gen bioinformatics for precision #oncology R&D. What does it take to be an inventor in #techbio today? 🧬 Skating to where the puck is going to be, not where it has been (to paraphrase Wayne Gretzky, the legendary hockey player) 🤝 Enable interdisciplinarity at scale to bring together Bio and AI for faster breakthroughs in oncology 👩🏻⚕️ Never losing sight of the real goal: transforming patient lives around the globe The journey continues, and the best is yet to come! A big thank you to the exceptional jury who helped shape this ranking Pierre Agostini, Karim Beguir, Camille GALAP, Olivier Ezratty, Valerie Sabah, Didier Samuel, Roxanne Varza, Claire Rougeulle, Pascale Ribon, and many others. We’re also super grateful to Héloïse Pons and Grallet Guillaume for leading this initiative. And now, let’s play “Where’s Waldo?” Can you spot our Co-founder & CEO Akpeli Nordor and several of our friends among the group of inventors? Drop a 👏 when you do! By the way, congratulations Fanny Jaulin, PhD, Melissa S. and Fabien Reyal! Find out more here: https://lnkd.in/dcBcnpH5

🚨 2025 Regulatory Updates: A turning point for oncology innovation? This year, regulatory changes will significantly impact the assessment of #biopharma innovation in Europe 🇪🇺 and France 🇫🇷–potentially reshaping the near future of #oncology care. Among these changes, key initiatives could accelerate drug development and market access. From advancing genomic #medicine in France to harmonizing drug evaluation across the European Union, these changes aim to enhance access, affordability, and outcomes for cancer patients–a crucial shift for #pharma companies seeking to bring next-generation oncology drugs to market faster. How do you think these policies will shape oncology innovation and patient care in 2025?

Glad to be part of Majycc Innovation Santé - UI Investissement portfolio, with a shared vision of driving innovation and transforming the healthcare industry! 🩺